Onxeo S.A.: Onxeo: Report on the Combined General Meeting of June 10, 2021
Shefali Agarwal, MD, a clinical development expert in oncology, is appointed Director of Onxeo
Regulatory News:
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, announced that the Combined General Meeting held today in camera adopted all the resolutions presented, in accordance with the recommendations of the Board of Directors.
The shareholders of the Company also renewed for three years the mandate of Mr. Thomas Hofstaetter, which expired at the end of this General Meeting and ratified the appointment of Mr. Julien Miara, representing Invus, to replace Mr. Jean-Pierre Kinet until the expiry of his mandate, at the end of the Meeting called to approve the accounts for the year ended December 31, 2021.
Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), ("Onxeo", "the Company" or "the Group"), a clinical-stage biotechnology company specializing in the development
Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
> Several major clinical milestones achieved in 2020 by AsiDNA, including promising initial results in combination with chemotherapy and the launch of a new study to evaluate the abrogation of resistance to a targeted therapy
> Cash position of €14.5 million at December 31, 2020 supplemented by €14.7 million in new financing obtained in early 2021
> Extended financial visibility through the end of 2022, enabling the expansion of clinical and industrial development of AsiDNA
Regulatory News:
https://us02web.zoom.us/webinar/register/WN T6v8Hc8TRU67rKXPrz2nXw
Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO) (Paris:ALONX) (NASDAQ OMX:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today reported its consolidated financial results for the fiscal ending December 31,